Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
“Be Youthful: Look Good, Feel Great – and Remain Young at Any Age,” Dr. Shino Bay Aguilera’s most recent publication in English, was just published in Spanish and is available on Amazon.com, through barnesandnoble.com, and electronically for Kindle. In addition, major bookstores in the United States can provide home delivery for individual orders.
The book provides insights and tips on the perfect ways to renew and restore your mind, body and, spirit – and describes what it means to actually be “youthful.” Dr. Shino Bay Aguilera is a world-renowned cosmetic and clinical dermatologist and the owner of the Shino Bay Cosmetic Dermatology, Plastic Surgery & Laser Institute. He is known as the #1 injector of Sculptra® in the United States and as the preferred choice of celebrities and public figures. Dr. Aguilera, originally from Panama and a former clothing model, became intrigued by people’s everlasting pursuit of the “fountain of youth” through his consultations. “Be Youthful” explores the many ways to clinically appear youthful, but also details his personal journey about the pursuit of happiness, peace, and self-confidence, which all lead to beauty.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7513051-dr-shino-bay-aguilera-book-be-youthful/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Orbis, the international nonprofit that unites the world in the fight against blindness, is proud to land its new, state-of-the-art Flying Eye Hospital in Shenyang, China this week to commence its first training program, running from September 5 - 23. Six years in the making, the third-generation Flying Eye Hospital is the world’s only mobile ophthalmic teaching hospital on board an MD-10 aircraft, donated by FedEx. Hundreds of experts have come together to combine the latest in avionics, hospital engineering, technology and clinical expertise to make the new Flying Eye Hospital a reality. It features modular design, 3D technology and live broadcast capabilities, which enables Orbis and their expert Volunteer Faculty to train more doctors, nurses and healthcare professionals—ultimately treating more people and restoring their sight.
“Today, I am incredibly proud that our Flying Eye Hospital can get to work on its first program,” Bob Ranck, Orbis CEO and President, said. “It is a testament to the hundreds of volunteers, global corporate partners, governments and other individuals who have worked tirelessly to make this unique aircraft a reality, and we thank them one and all. Our mission at Orbis is to bring the world together to fight blindness, and the Flying Eye Hospital is an important tool for achieving this. It is an equal-parts teacher, envoy and advocate for the right to sight. We are excited to start this new chapter in Orbis history here in Shenyang, China.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7316251-orbis-flying-eye-hospital/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
HMR Weight Management Services (HMR), a subsidiary of Merck, has been named a No. 1 Best Fast Weight-Loss Diet in U.S. News & World Report’s Best Diets of 2016 rankings. This is the first year U.S. News has published the Best Fast Weight-Loss Diet category. HMR also held its position as the No. 2 Best Weight-Loss Diet in the annual rankings list for the second year in a row. HMR Programs focus on helping people lose weight quickly while teaching the healthy lifestyle skills needed for long-term weight management.
“HMR programs excel at providing the jump start many people need when beginning a healthier lifestyle program,” said Carol Addy, M.D. MMSc, Chief Medical Officer at HMR. “A common misconception is that losing weight quickly is not healthy, not sustainable, and will just lead to future weight re-gain. To the contrary, numerous clinical studies demonstrate that following a lifestyle change program which promotes fast initial weight loss can result in better long-term success.” Addy added, “On the HMR Program, people can lose weight without feeling hungry. Our programs achieve fast weight loss in a livable way by encouraging people to eat more and stay satisfied, which makes it easier to stick to the program in the short-term, and over the long haul.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7670751-hmr-program-named-best-weight-loss-diet/
It’s inevitable that we’re all going to age, but Dr. Ronald Kaiser has discovered a way to make it enjoyable. In his new book Rejuvenaging: The Art and Science of Growing Older with Enthusiasm, Dr. Kaiser lays out the path to not only embracing our later years but making them the best half of our lives. Drawing on more than a half-century of clinical experience, and 80 years of living, Kaiser shares his simple plan to success. Find out more at http://www.thementalhealthgym.com/ Non-Fiction/Self Help
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
